Applied Spectral Imaging Announces the Launch of the GenASIs Automated Imaging Platforms for Genetic and Pathology Analysis
The GenASIs advanced cytogenetic and pathology platforms are the foundation of ASI’s new offering. With its superior imaging and analysis capabilities, ASI provides state of the art diagnostic aids, offering cytogeneticists and pathologists accurate genetic and pathology analysis.
Carlsbad, CA, December 24, 2011 --(PR.com)-- Applied Spectral Imaging (ASI, www.spectral-imaging.com) announced today general availability of the GenASIs automated imaging platforms for genetic and pathology analysis.
The GenASIs advanced cytogenetic and pathology platforms are the foundation of ASI’s new offering. With its superior imaging and analysis capabilities, ASI provides state of the art diagnostic aids, offering cytogeneticists and pathologists accurate genetic and pathology analysis.
GenASIs enables automated pathology tissue analysis for primary diagnostics, creating reproducible and reliable results. GenASIs can grow with current and future laboratory needs. The GenASIs platforms offer a comprehensive solution ensuring reliability and quality results every time, while allowing cytogeneticists, pathologists and technologists to focus on the clinical rather than the technical components.
ASI’s advanced solutions accommodate the market demand for faster, more powerful imaging and analysis tools catering to the growing need for high throughput solutions empowering laboratories to do more with less.
Limor Shiposh, ASI’s CEO, said: “I am confident that the introduction of our new GenASIs platforms and product suite will allow us to further broaden our market presence and establish ASI as the leader in image acquisition and analysis worldwide for the cytogenetic and pathology markets.” Limor further added that, “With quality service being in our genes we will continue to listen to our customers, understand their needs and provide them with superior solutions. Our ongoing success is built on setting new industry standards of quality, reliability and service with our GenASIs offering. We are gratified with the feedback received from customers who have experienced the GenASIs platforms. This feedback has far exceeded our expectations.”
About ASI
Applied Spectral Imaging (ASI) is the maker of the GenASIs automated imaging platforms for genetic and pathology analysis. ASI complies with the highest international quality standards including ISO, CE, CMDCAS and 21CFR part 820. GenASIs is FDA cleared for clinical applications such as UroVysion, HER2/neu FISH, CEP XY, Karyotyping and FISH. ASI has been the industry's leading provider of microscopy imaging solutions since 1993. It has over 30 registered patents in the US, Europe, Japan and the rest of the world. With worldwide offices in the US, Europe and Asia, ASI has built a global network of over 50 distributors.
###
For More Information Contact –
Mr. Dror Armon, Director Sales and Marketing
Phone: +1(800) 611-3466
Fax: +1 760 929 2842
E-mail: Dror@spectral-imaging.com
www.spectral-imaging.com
The GenASIs advanced cytogenetic and pathology platforms are the foundation of ASI’s new offering. With its superior imaging and analysis capabilities, ASI provides state of the art diagnostic aids, offering cytogeneticists and pathologists accurate genetic and pathology analysis.
GenASIs enables automated pathology tissue analysis for primary diagnostics, creating reproducible and reliable results. GenASIs can grow with current and future laboratory needs. The GenASIs platforms offer a comprehensive solution ensuring reliability and quality results every time, while allowing cytogeneticists, pathologists and technologists to focus on the clinical rather than the technical components.
ASI’s advanced solutions accommodate the market demand for faster, more powerful imaging and analysis tools catering to the growing need for high throughput solutions empowering laboratories to do more with less.
Limor Shiposh, ASI’s CEO, said: “I am confident that the introduction of our new GenASIs platforms and product suite will allow us to further broaden our market presence and establish ASI as the leader in image acquisition and analysis worldwide for the cytogenetic and pathology markets.” Limor further added that, “With quality service being in our genes we will continue to listen to our customers, understand their needs and provide them with superior solutions. Our ongoing success is built on setting new industry standards of quality, reliability and service with our GenASIs offering. We are gratified with the feedback received from customers who have experienced the GenASIs platforms. This feedback has far exceeded our expectations.”
About ASI
Applied Spectral Imaging (ASI) is the maker of the GenASIs automated imaging platforms for genetic and pathology analysis. ASI complies with the highest international quality standards including ISO, CE, CMDCAS and 21CFR part 820. GenASIs is FDA cleared for clinical applications such as UroVysion, HER2/neu FISH, CEP XY, Karyotyping and FISH. ASI has been the industry's leading provider of microscopy imaging solutions since 1993. It has over 30 registered patents in the US, Europe, Japan and the rest of the world. With worldwide offices in the US, Europe and Asia, ASI has built a global network of over 50 distributors.
###
For More Information Contact –
Mr. Dror Armon, Director Sales and Marketing
Phone: +1(800) 611-3466
Fax: +1 760 929 2842
E-mail: Dror@spectral-imaging.com
www.spectral-imaging.com
Contact
Applied Spectral Imaging
Aviva Katz
1 (760) 929-2840
www.spectral-imaging.com
Aviva Katz
1 (760) 929-2840
www.spectral-imaging.com
Contact
Categories